A Randomized Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In The Treatment Of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET).

Trial Profile

A Randomized Double-Blind Phase III Study of RAD001 10mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In The Treatment Of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANT-3
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2017 Results of pooled data assessing effectiveness of sunitinib and everolimus in patients with pancreatic neuroendocrine tumours from two trial (RADIANT-3 and A6181111 ), were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 10 Jun 2017 Biomarkers information updated
    • 12 Sep 2016 Results of final overall survival and biomarker analysis published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top